Stifel says Arvinas management are “clearly signaling” that bavdegalutamide has a competitive profile into the disclosure of bavdegalutamide’s phase 1/2 update in prostrate cancer at ESMO23 on October 20-24 and “are excited to share the data.” The firm thinks a greater than 7m radiographic progression-free survival disclosure will be “sufficient to draw investor interest back to this program” and sufficient to support its phase 3 program and competitive profile versus emerging therapies. Stifel keeps a Buy rating and $68 price target on Arvinas shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas price target lowered to $72 from $77 at Citi
- Oppenheimer Says These 2 Beaten-Down Stocks Could Double Your Money — Here’s Why They Could Rebound
- Arvinas shares remain ‘grossly undervalued,’ says Capital One
- Arvinas price target lowered to $70 from $81 at Piper Sandler
